Wardah S. Alharbi

Ms. Wardah S. Alharbi

King Abdullah International Medical Research Center, Riyadh, Ar Riyāḑ, Saudi Arabia
+2
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in Human Genomics
Verified
Journal Article
Open access
PDF file
WAWardah S. Alharbi
Wardah S. Alharbi
MRMamoon Rashid
Mamoon Rashid
Genomics is advancing towards data-driven science. Through the advent of high-throughput data generating technologies in human genomics, we are overwhelmed with the heap of genomic data. To extract knowledge and pattern out of this genomic data, artificial intelligence especially deep learning methods has been instrumental. In the current review, we address development and application of deep learning methods/models in different subarea of human genomics. We assessed over- and under-charted area of genomics by deep learning techniques. Deep learning algorithms underlying the genomic tools have been discussed briefly in later part of this review. Finally, we discussed briefly about the late application of deep learning tools in genomic. Conclusively, this review is timely for biotechnology or genomic scientists in order to guide them why, when and how to use deep learning methods to analyse human genomic data.

26 September 2019 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
MAMajid Alfadhel
Majid Alfadhel
Muhammad UmairMuhammad Umair
Muhammad Umair
BABader Almuzzaini
Bader Almuzzaini
SASaif Alsaif
Saif Alsaif
SASulaiman A. AlMohaimeed
Sulaiman A. AlMohaimeed
BTBrahim Tabarki
Brahim Tabarki
Background: Biotin–thiamine‐responsive basal ganglia disease (BTBGD) is an autosomal recessive neurometabolic disorder mostly presented in children. The disorder is described as having subacute encephalopathy with confusion, dystonia, and dysarthria triggered by febrile illness that leads to neuroregression and death if untreated. Using biotin and thiamine at an early stage of the disease can lead to significant improvement.Methods: BTBGD is a treatable disease if diagnosed at an early age and has been frequently reported in Saudi population. Keeping this in mind, the current study screened 3000 Saudi newborns for the SLC19A3 gene mutations using target sequencing, aiming to determine the carrier frequency in Saudi Population and whether BTBGD is a good candidate to be included in the newborn‐screened disorders.Results: Using targeted gene sequencing, DNA from 3000 newborns Saudi was screened for the SLC19A3 gene mutations using standard methods. Screening of the SLC19A3 gene revealed a previously reported heterozygous missense mutation (c.1264A>G (p.Thr422Ala) in six unrelated newborns. No probands having homozygous pathogenic mutations were found in the studied cohort. The variant has been frequently reported previously in homozygous state in Saudi population, making it a hot spot mutation. The current study showed that the carrier frequency of SLC19A3 gene mutation is 1 of 500 in Saudi newborns.Conclusion: For the first time in the literature, we determined the carrier frequency of SLC19A3 gene mutation in Saudi population. The estimated prevalence is too rare in Saudi population (at least one in million); therefore, the data are not in favor of including such very rare disorders in newborn screening program at population level. However, a larger cohort is needed for a more accurate estimate.

2 November 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
MRMamoon Rashid
Mamoon Rashid
Rizwan AliRizwan Ali
Rizwan Ali
BABader Almuzzaini
Bader Almuzzaini
HSHao Song
Hao Song
AAAlshaimaa AlHallaj
Alshaimaa AlHallaj
MBMohamed Boudjelal
Mohamed Boudjelal
The colony stimulating factor 2 receptor subunit beta (CSF2RB) is the common signaling subunit of the cytokine receptors for IL-3, IL-5, and GM-CSF. Several studies have shown that spontaneous and random mutants of CSF2RB can lead to ligand independence in vitro. To date, no report(s) have been shown for the presence of potentially transforming and oncogenic CSF2RB mutation(s) clinically in cancer patients until the first reported case of a leukemia patient in 2016 harboring a germline-activating mutation (R461C). We combined exome sequencing, pathway analyses, and functional assays to identify novel somatic mutations in KAIMRC1 cells and breast tumor specimen. The patient’s peripheral blood mononuclear cell (PBMC) exome served as a germline control in the identification of somatic mutations. Here, we report the discovery of a novel potentially transforming and oncogenic somatic mutation (S230I) in the CSF2RB gene of a breast cancer patient and the cell line, KAIMRC1 established from her breast tumor tissue. KAIMRC1 cells are immortalized and shown to survive and proliferate in ligand starvation condition. Immunoblot analysis showed that mutant CSF2RB signals through JAK2/STAT and PI3K/mTOR pathways in ligand starvation conditions. Screening a small molecule kinase inhibitor library revealed potent JAK2 inhibitors against KAIMRC1 cells. We, for the first time, identified a somatic, potentially transforming, and oncogenic CSF2RB mutation (S230I) in breast cancer patients that seem to be an actionable mutation leading to the development of new therapeutics for breast cancer.

1 July 2019 in Journal of Infection and Public Health
Verified
Journal Article
Open access
AKAnis Khan
Anis Khan
MAMohammed AlBalwi
Mohammed AlBalwi
IAIbraheem AlAbdulkareem
Ibraheem AlAbdulkareem
AAAbdulrahman AlMasoud
Abdulrahman AlMasoud
AAAbdulrahman AlAsiri
Abdulrahman AlAsiri
HBHanan H. Balkhy
Hanan H. Balkhy

14 April 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
TATaghrid Aloraini
Taghrid Aloraini
AAAbdulrhman Aljouie
Abdulrhman Aljouie
RARashed Alniwaider
Rashed Alniwaider
WAWardah S. Alharbi
Wardah S. Alharbi
LALamia Alsubaie
Lamia Alsubaie
AAAhmed Alfares
Ahmed Alfares

1 April 2017 in Human Immunology
Verified
Journal Article
Closed access
MAMohammed AlBalwi
Mohammed AlBalwi
AHAli I. Hadadi
Ali I. Hadadi
WAWardah S. Alharbi
Wardah S. Alharbi
MBMariam Ballow
Mariam Ballow
AAAbdulrahman AlAsiri
Abdulrahman AlAsiri
AHAli H. Hajeer
Ali H. Hajeer